The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Type I or II Hereditary Angioedema (HAE) adolescent and adult post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.
Study Type
EXPANDED_ACCESS
Oral Plasma Kallikrein Inhibator
KalVista Investigative Site
Scottsdale, Arizona, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.